Filing Flows › Adaptive Biotechnologies (ADPT) › R&D spending
Adaptive Biotechnologies (ADPT) R&D spending by quarter
Adaptive Biotechnologies' R&D spending was $18.6M in Q3 2026 (third quarter 2026), -3% from Q2 2026. Over the last 7 quarters it ranged from $18.6M (Q3 2026) to $24.2M (Q1 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $18.6M | -3% | -21% |
| Q2 2026 | $19.2M | -19% | -21% |
| Q1 2026 | $23.6M | +9% | -2% |
| Q4 2025 | $21.8M | -8% | — |
| Q3 2025 | $23.7M | -2% | — |
| Q2 2025 | $24.1M | -0.3% | — |
| Q1 2025 | $24.2M | — | — |
Q3 2026 at a glance
Adaptive Biotechnologies, Q3 2026: revenue $83.9M (-11% year over year), operating margin -0.5%, net earnings $2.8M, operating cash flow $9.6M. The chart follows the revenue to costs, profit and cash.
Questions
What is Adaptive Biotechnologies' R&D spending?
Adaptive Biotechnologies' R&D spending was $18.6M in Q3 2026 (third quarter 2026), -3% from Q2 2026.
How has Adaptive Biotechnologies' R&D spending changed?
Over the last 7 quarters it ranged from $18.6M (Q3 2026) to $24.2M (Q1 2025).
Q3 2026 results → · How Adaptive Biotechnologies makes money →